Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06383390 · ClinicalTrials.gov registry record · Phase 3
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
A Phase 3 study of Chronic Kidney Disease (CKD) and Atherosclerotic Cardiovascular Disease (ASCVD), sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 10,000
- Enrollment target
- 20
- Study locations
NCT06383390: Active Phase 3 study of Chronic Kidney Disease (CKD) and Atherosclerotic Cardiovascular Disease (ASCVD), sponsored by Eli Lilly and Company.
NCT06383390 is a Phase 3 study of Chronic Kidney Disease (CKD) and Atherosclerotic Cardiovascular Disease (ASCVD) that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 10,000 participants, above the 702-participant average among 14 other Chronic Kidney Disease (CKD) trials with a reported enrollment target (1325% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06383390, a Phase 3 study of Chronic Kidney Disease (CKD) and Atherosclerotic Cardiovascular Disease (ASCVD), is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 10,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Primary Outcome
A composite endpoint includes nonfatal myocardial infarction (MI), nonfatal stroke, cardiovascular (CV) death, or hospitalization or urgent visit due to heart failure (HF).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Retatrutide
Study Locations (20)
Arizona
- Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC - Gilbert
- Sun City Clinical Research - Glendale
- Arizona Kidney Disease & Hypertension Center (AKDHC) - Thunderbird - Glendale
- Helios Clinical Research - SAZ-PDV-026 - Paradise Valley
- Banner University Medical Center Phoenix - Phoenix
- Phoenix Clinical LLC - Phoenix
- Elite Clinical Studies, LLC - Phoenix
- Absolute Clinical Research - Phoenix
- Scottsdale Clinical Trials - Scottsdale
- Clinical Research Institute of Arizona (CRI) - Sun City West - Sun City West
- Synexus Clinical Research US, Inc./Orange Grove Family Practice - Tucson
Alabama
- Alabama Kidney Research - Alabaster
- Central Research Associates - Birmingham
- Alliance for Multispecialty Research, LLC - Daphne
- Nephrology Consultants - Huntsville
- Alliance for Multispecialty Research, LLC - Mobile
California
- Kidney & Hypertension Center - Apple Valley - Apple Valley
- Invivo - Bakersfield - Bakersfield
- American Institute of Research - Beverly Hills
Arkansas
- Cardiology and Medicine Clinic - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2024-04-30 |
| Est. Completion | 2029-02 |
| Phase | Phase 3 |
What the registry record for NCT06383390 still lists
NCT06383390 is an interventional study that assigns participants to a tested intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 702-participant average among 14 other Chronic Kidney Disease (CKD) trials with a reported enrollment target (1325% higher).
The record links to 2 conditions, with Chronic Kidney Disease (CKD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06383390 names 20 study sites across 4 states, led by Arizona, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT06383390 about?
NCT06383390 is a clinical study titled "The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)". The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease an...
What is the current status of trial NCT06383390?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 10,000 participants. The study started on 2024-04-30. Estimated completion is 2029-02.
What conditions does trial NCT06383390 study?
This clinical trial studies the following conditions: Chronic Kidney Disease (CKD), Atherosclerotic Cardiovascular Disease (ASCVD).
What interventions are being tested in trial NCT06383390?
The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG).
Who is sponsoring clinical trial NCT06383390?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06383390 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease (CKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06383390's enrollment target sits among peer trials
10,000 1st of 14 higher than 14 of 14 other Chronic Kidney Disease (CKD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease (CKD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
COMPLETED · Phase 3
-
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
COMPLETED · Phase 3
-
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
RECRUITING
-
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
RECRUITING · Phase 1
-
Exercise and Monitoring With Post-Hospitalization Muscle Atrophy to Sustain Intrinsic Capacity and Strength
RECRUITING · NA
-
Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI